@article {7993,
	title = {Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer},
	journal = {Cancer Chemotherapy and Pharmacology},
	volume = {56},
	year = {2005},
	note = {Cited By :4Export Date: 21 February 2017},
	month = {2005},
	pages = {521 - 528},
	abstract = {The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. Successive cohorts of AS-SCLC patients were treated with irinotecan administered as a single 1-h infusion in combination with fixed doses of cisplatin (20 mg/m 2) and etoposide (75 mg/m2), both given for three consecutive days (ECI regimen). Irinotecan dose was escalated from 60 mg/m 2 by 40-mg/m2 increments. At mid-step between the maximum tolerated dose (MTD) and the previous dose level, patients were randomized for the day of administration of irinotecan (day 1 vs day 3). A total of 36 AS-SCLC patients received 166 courses of treatment at four dose levels. The MTD of irinotecan was 140 mg/m2 (three dose-limiting toxicities, DLTs), and the recommended optimal dose (ROD) 120 mg/m2 (two DLTs). DLTs were febrile neutropenia and grade 3 diarrhea. Other toxicities were mild. No difference in toxicity was seen between the two time schedules. A 77\% (95\% CI 63.25-90.75\%) response rate was recorded among 31 evaluable patients and the median survival was 12 months. The ECI regimen was well tolerated and showed considerable activity in patients with AS-SCLC. Phase II/III evaluation is ongoing. {\textcopyright} Springer-Verlag 2005.},
	keywords = {Cisplatin, Etoposide, Irinotecan, Phase I, Small-cell lung cancer},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-27644521908\&doi=10.1007\%2fs00280-004-0994-8\&partnerID=40\&md5=5dd21ff01a823760ff81c2d6dfa0537b},
	author = {Briasoulis, E. and Samantas, E. and Kalofonos, H. and Skarlos, D. and Makatsoris, T. and Christodoulou, C. and Fountzilas, G. and Bamias, A. and Dimopoulos, M.A. and Kosmidis, P. and N. Pavlidis}
}
